Skip to content
MarketScale
‹ Back to IndustriesSciences

Laying Out the Landscape in Today’s Patient Monitoring

More and more hospital environments rely on continuous, high-quality data to support faster clinical decisions, but much of today’s patient monitoring still varies widely by unit, device, and workflow. This episode kicks off a five-part Health and Life Sciences at the Edge series exploring The Future of Patient Monitoring. Intel’s Kaeli Tully, Solutions Engineer…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Michelle Dawn Mooney · Continuous Patient MonitoringCritical CareEarly Patient Deterioration DetectionIcu Monitoring
Share

Key takeaways

01

More and more hospital environments rely on continuous, high-quality data to support faster clinical decisions, but much of today’s patient monitoring still varies widely by unit, device, and workflow.

02

This episode kicks off a five-part Health and Life Sciences at the Edge series exploring The Future of Patient Monitoring.

03

Intel’s Kaeli Tully, Solutions Engineer…

More and more hospital environments rely on continuous, high-quality data to support faster clinical decisions, but much of today’s patient monitoring still varies widely by unit, device, and workflow. This episode kicks off a five-part Health and Life Sciences at the Edge series exploring The Future of Patient Monitoring. Intel’s Kaeli Tully, Solutions Engineer for Healthcare and Life Sciences, and Dr. Sanjay Subramanian, Critical Care Physician and CEO/Founder of Omnicure, speak with Michelle Dawn Mooney about what patient monitoring looks like on the front lines and what it will take to spot decline earlier across the hospital.

Dr. Subramanian frames monitoring as a continuum across care intensity, noting that “hospitals are sort of and have always existed in two segments… the low-intensity segment and the high-intensity, which is the intensive care units.” While most patients receive some level of vital signs monitoring, he explains that “the frequency with which that happens is highly variable,” even though deterioration can occur without warning. In his view, “all patients deserve probably continuous monitoring,” but the barrier is often cost and operational feasibility.

The conversation also highlights why monitoring matters most outside the ICU, especially when hospitals face crowding and staffing gaps. Dr. Subramanian emphasizes that critical care is strained by workforce realities, sharing that “most, I would say 80% of ICUs in the country, don’t have dedicated 24-7 staffing by board-certified intensive care physicians,” which accelerates interest in telecritical care and tele-ICU models. He describes how “ICU without walls” expands critical care beyond a fixed unit, recognizing that patients “deteriorate on the floors… in the emergency rooms, the operating theaters, and the PACUs.” The goal becomes extending expertise and visibility wherever patients are.

From an infrastructure perspective, the episode digs into the challenge of heterogeneous device ecosystems and inconsistent access to data streams. Dr. Subramanian notes that “it becomes easier if the technology stack is homogenous,” but many hospitals have “multiple devices of different ages” and cannot “reliably access the data from them.” Looking forward, he identifies a clear priority: “We need to solve for getting access to data reliably, continuously, and that’s high fidelity at scale,” and pair it with “the appropriate workflows to make that data actionable.”

Learn more about patient monitoring innovation by connecting with Kaeli Tully and Dr. Sanjay Subramanian on LinkedIn, or by visiting Omnicure and Intel Health and Life Sciences.

Subscribe to this channel on Apple Podcasts and Spotify to hear more from the Intel Network and Edge Solutions Group.

About the author

MD

Michelle Dawn Mooney is a media professional and host known for her work in broadcast journalism and B2B content.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Sciences expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics has hired Neil Anderson, Ph.D. as the Chief Revenue Officer to spearhead the commercialization of its nanoimprint flat optics platform. The platform is intended for use in AI datacenters, augmented reality (AR), and life sciences applications. Anderson's experience in photonics is expected to aid Myrias Optics in expanding its market presence in these sectors.

  • 01Myrias Optics appointed Neil Anderson, Ph.D. as CRO to lead the commercialization of its technology.
  • 02The company focuses on nanoimprint flat optics for AI datacenters, AR, and life sciences.
  • 03Neil Anderson brings extensive photonics expertise to support Myrias Optics' growth.

Jul 31, 2026

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

MD
Michelle Dawn Mooney

Michelle Dawn Mooney is a media professional and host known for her work in broadcast journalism and B2B content.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512